Table 1 : Variations in the epidemiological, risk factors, and clinicopathological characteristics
between group 1 (cisplatin treated patients) and group II (cisplatin with paclitaxel treated
patients).
| Patient characteristic |
Parameter | Group 1 N=25 (%) |
Group II N=30 (%) | P-value |
| Age (years) | Mean | 58.8 | 55.6 | |
| ≤60 | 14 (56%) | 20 (66.7%) | 0.6 | |
| >60 | 11 (44%) | 10 (33.3%) | ||
| Sex | Male | 20 (80%) | 22 (73·3%) | 0.8 |
| Female | 5 (20%) | 8 (26.7%) | ||
| Smoking | Smoker | 20 (80%) | 10 (33.3%) | 0.001 |
| Non-smoker | 5 (20%) | 20 (66.7%) | ||
| Bilharzias | Positive | 16 (64%) | 11 (36.7%) | 0.08 |
| Negative | 9 (36%) | 19 (63.3%) | ||
| Complaint | Hematuria | 17 (68%) | 24 (80%) | 0.9 |
| Noctnuria | 3 (12%) | 11 (36.7%) | ||
| Dysuria | 3 (12%) | 19 (63.3%) | ||
| Burning Micturition | 8 (32%) | 4 (13.3%) | ||
| Increase Frequency | 3 (12%) | 13 (43.3%) | ||
| Pelvic pain | 2 (8%) | 10 (33.3%) | ||
| ECOG * | PS_0 | 21 (84%) | 25 (83.3%) | 0.8 |
| PS_1 | 4 (16%) | 5 (16.7%) | ||
| Tumor site | Anterior wall | 6 (24%) | 1 (3.3%) | 0.9 |
| Posterior wall | 0 (0%) | 4 (13.3%) | ||
| Lt. Lateral wall | 7 (28%) | 4 (13.3%) | ||
| Rt. Lateral wall | 5 (20%) | 13 (43.3%) | ||
| Bladder dome | 0 (0%) | 3 (10%) | ||
| Bladder neck | 1 (4%) | 2 (6.7%) | ||
| Multiple lesions | 6 (24%) | 3 (10%) | ||
| Tumor size | <3 cm | 4 (16%) | 18 (60%) | 0.003 |
| 3-5 cm | 16 (64%) | 10 (33.3%) | ||
| >5 cm | 5 (20%) | 2 (6.7%) | ||
| Histopathology | TCC* | 12 (48%) | 14 (46.7%) | 0.7 |
| Sq. C. C.* | 8 (32%) | 6 (20%) | ||
| TCC with Sq. differentiation |
2 (8%) | 8 (26.7%) | ||
| TCC with glandular differentiation |
0 (0%) | 2 (6.7%) | ||
| Adenocarcinoma | 2 (8%) | 0 (0%) | ||
| Anaplastic cell carcinoma | 1 (4%) | 0 (0%) | ||
| Stage | T2a | 4 (16%) | 15 (50%) | 0.04 |
| T2b | 10 (40%) | 7 (23.3%) | ||
| T3a | 5 (20%) | 6 (20%) | ||
| T3b-4 | 6 (24%) | 2 (6.7%) | ||
| Tumor differentiation |
Well differentiated | 3 (12%) | 4 (13.3%) | 0.9 |
| Moderately differentiated | 13 (52%) | 14 (46.7%) | ||
| Poorly differentiated | 9 (36%) | 12 (40%) | ||
| Previous surgery |
TUR | 24 (96%) | 30 (100%) | 0.9 |
| Partial cystectomy | 1 (4%) | 0 (0%) | ||
| TUR | Complete | 18 (72%) | 20 (66.7%) | 0.9 |
| Incomplete | 7 (28%) | 10 (33.3%) | ||
ECOG: Eastern Cooperative Oncology Group; TCC: Transitional Cell Carcinoma;
Sq.C.C: Squamous cell carcinoma; TUR: Transurethral resection